TAS 5315

Drug Profile

TAS 5315

Alternative Names: TAS-5315

Latest Information Update: 07 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiho Pharmaceutical
  • Class Anti-inflammatories; Antirheumatics
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 07 Aug 2018 Taiho Pharmaceutical plans a phase II trial for Rheumatoid arthritis (Treatment-experienced) in Japan (NCT03605251)
  • 03 Nov 2017 Pharmacodynamics data from preclinical studies in Rheumatoid Arthritis presented at the 81st American College of Rheumatology and the 52nd Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2017)
  • 15 Mar 2017 3229558 - QC incoporated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top